Trials / Completed
CompletedNCT01895387
Dietary Effects on Circulating Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity and Enzyme Activity in Peripheral Blood Mononuclear Cells (PBMCs) in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes
Replacing With Whole Grains and Legumes Reduces Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activities in Plasma and Peripheral Blood Mononuclear Cells in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 39 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
We determined the effects of dietary intervention (replacement of refined rice with whole grains and legumes and a high intake of vegetables) on circulating Lp-PLA2 activity and enzyme activity in peripheral blood mononuclear cells (PBMCs) in patients with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or newly-diagnosed type 2 diabetes.
Detailed description
Ninety-nine patients with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or newly-diagnosed type 2 diabetes were randomly assigned to either a control group (usual diet with refined rice) or the whole grain group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Dietary intervention-whole grains and legumes | Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. |
| DIETARY_SUPPLEMENT | Dietary intervention-Refined rice | Subjects in the control group maintained their usual diet of refined rice |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-06-01
- Completion
- 2012-10-01
- First posted
- 2013-07-10
- Last updated
- 2013-07-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01895387. Inclusion in this directory is not an endorsement.